Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

6.67
Delayed Data
As of May 23
 +0.13 / +1.99%
Today’s Change
5.02
Today|||52-Week Range
13.00
-15.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$835.3M

Company Description

Merrimack Pharmaceuticals, Inc. engages in discovering, developing and preparing to commercialize innovative medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its offers its first commercial product, Onivyde, which is a novel encapsulation of the marketed chemotherapy drug irinotecan in liposomal formulation. The company was founded by Anthony J. Sinskey, Gavin MacBeath and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Contact Information

Merrimack Pharmaceuticals, Inc.
One Kendall Square, Building 700
Cambridge Massachusetts 02139
P:(617) 441-1000
Investor Relations:
(617) 441-7602

Employees

Shareholders

Individual stakeholders7.68%
Mutual fund holders40.78%
Other institutional28.33%

Top Executives

Robert J. MulroyPresident, Chief Executive Officer & Director
William M. McClementsHead-Corporate Operations
Yasir B. Al-WakeelCFO & Head-Corporate Development
Jeffrey A. MunsieVice President & General Counsel
Eliel BayeverVice President & Medical Director-MM-398